CN109715206B - 结合蛋白及其使用方法 - Google Patents

结合蛋白及其使用方法 Download PDF

Info

Publication number
CN109715206B
CN109715206B CN201780030436.7A CN201780030436A CN109715206B CN 109715206 B CN109715206 B CN 109715206B CN 201780030436 A CN201780030436 A CN 201780030436A CN 109715206 B CN109715206 B CN 109715206B
Authority
CN
China
Prior art keywords
seq
antibody
amino acid
gfral
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780030436.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN109715206A (zh
Inventor
沈文彦
唐杰
王艳
雨果·马特恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NGM Biopharmaceuticals Inc
Original Assignee
NGM Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NGM Biopharmaceuticals Inc filed Critical NGM Biopharmaceuticals Inc
Priority to CN202311479185.4A priority Critical patent/CN117986363A/zh
Publication of CN109715206A publication Critical patent/CN109715206A/zh
Application granted granted Critical
Publication of CN109715206B publication Critical patent/CN109715206B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN201780030436.7A 2016-03-31 2017-03-03 结合蛋白及其使用方法 Active CN109715206B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311479185.4A CN117986363A (zh) 2016-03-31 2017-03-03 结合蛋白及其使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662316516P 2016-03-31 2016-03-31
US62/316,516 2016-03-31
PCT/US2017/020654 WO2017172260A1 (en) 2016-03-31 2017-03-03 Binding proteins and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311479185.4A Division CN117986363A (zh) 2016-03-31 2017-03-03 结合蛋白及其使用方法

Publications (2)

Publication Number Publication Date
CN109715206A CN109715206A (zh) 2019-05-03
CN109715206B true CN109715206B (zh) 2023-11-07

Family

ID=59966343

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780030436.7A Active CN109715206B (zh) 2016-03-31 2017-03-03 结合蛋白及其使用方法
CN202311479185.4A Pending CN117986363A (zh) 2016-03-31 2017-03-03 结合蛋白及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311479185.4A Pending CN117986363A (zh) 2016-03-31 2017-03-03 结合蛋白及其使用方法

Country Status (18)

Country Link
US (4) US10174119B2 (https=)
EP (1) EP3436068A4 (https=)
JP (3) JP7021099B2 (https=)
KR (2) KR102370762B1 (https=)
CN (2) CN109715206B (https=)
AU (3) AU2017241161C1 (https=)
BR (1) BR112018068898A2 (https=)
CA (1) CA3016035A1 (https=)
CL (1) CL2018002687A1 (https=)
CO (1) CO2018009995A2 (https=)
IL (1) IL261666B2 (https=)
MX (2) MX2018011503A (https=)
MY (1) MY194669A (https=)
PE (1) PE20190126A1 (https=)
PH (1) PH12018501882A1 (https=)
SG (1) SG11201807279QA (https=)
TW (2) TWI815793B (https=)
WO (1) WO2017172260A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20190126A1 (es) 2016-03-31 2019-01-17 Ngm Biopharmaceuticals Inc Proteinas de union y metodos de uso de las mismas
EP3526346A1 (en) * 2016-10-12 2019-08-21 Janssen Biotech, Inc. Methods for screening for modulators of gdf15-like biological activity
CA3106948A1 (en) * 2018-08-10 2020-02-13 Novartis Ag Gfral extracellular domains and methods of use
EP3920955A4 (en) * 2019-02-05 2023-02-22 The Trustees of the University of Pennsylvania GDNF FAMILY RECEPTOR-A-LIKE PEPTIDE LIGANDS (GFRAL)
US20220213187A1 (en) * 2019-05-08 2022-07-07 Agilvax Inc. Compositions and methods related to xct antibodies
US12594330B2 (en) 2019-06-04 2026-04-07 Regents Of The University Of Minnesota Anti-opioid compounds and methods of making and using same
US20220332805A1 (en) * 2019-09-11 2022-10-20 University Of Cincinnati Treatment of Skin Blistering Diseases Using Antibodies
WO2021246773A1 (ko) * 2020-06-04 2021-12-09 재단법인대구경북과학기술원 Gfral 길항 항체 및 이의 용도
KR102708796B1 (ko) 2020-06-04 2024-09-26 재단법인대구경북과학기술원 Gfral 길항 항체 및 이의 용도
US20240124606A1 (en) * 2021-02-22 2024-04-18 Northwestern University Anti-cd73 monoclonal antibodies
WO2022207785A1 (en) * 2021-03-31 2022-10-06 Kymab Limited Antibodies to gfral
CA3215737A1 (en) 2021-03-31 2022-10-06 Cambridge Enterprise Limited Therapeutic inhibitors of gdf15 signalling
US20240368286A1 (en) * 2021-06-30 2024-11-07 Shanghai Jmt-Bio Technology Co., Ltd. Anti-gfral antibody and application thereof
WO2023018803A1 (en) 2021-08-10 2023-02-16 Byomass Inc. Anti-gdf15 antibodies, compositions and uses thereof
TW202313694A (zh) 2021-09-10 2023-04-01 美商恩格姆生物製藥公司 治療癌症以及腫瘤相關之體重減輕及惡病質之方法
WO2023048425A1 (ko) * 2021-09-24 2023-03-30 재단법인대구경북과학기술원 친화도가 개선된 gfral 길항 항체 및 이의 용도
KR102864956B1 (ko) 2021-09-24 2025-09-30 재단법인대구경북과학기술원 친화도가 개선된 gfral 길항 항체 및 이의 용도
US20250382359A1 (en) 2021-12-22 2025-12-18 Byomass Inc. Targeting gdf15-gfral pathway
GEAP202416592A (en) * 2022-02-03 2024-11-11 Igm Biosciences Inc Anti-cd38 binding molecules and uses thereof
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
CA3246509A1 (en) * 2022-03-28 2023-10-05 Coherus Biosciences, Inc. ANTI-ILT4 COMPOSITIONS AND METHODS
CN118580334A (zh) * 2023-03-03 2024-09-03 北京志道生物科技有限公司 一种多肽分子
IT202300006387A1 (it) * 2023-03-31 2024-10-01 Univ Degli Studi Roma La Sapienza Inibitore del recettore gfral per uso nel trattamento della sclerosi laterale amiotrofica
US20250074991A1 (en) 2023-07-31 2025-03-06 Ngm Biopharmaceuticals, Inc. Methods of treating nausea and vomiting disorders using anti-gfral antibodies
CN117209596B (zh) * 2023-09-01 2024-11-26 中国农业科学院兰州兽医研究所 抗非洲猪瘟病毒p72蛋白中和活性单克隆抗体2c9及其应用
WO2025179086A1 (en) * 2024-02-23 2025-08-28 Children's National Medical Center Anti-ret antibodies as cancer therapeutics and diagnostic tools
WO2025244462A1 (ko) * 2024-05-24 2025-11-27 한국과학기술원 Gfral을 표적으로 하는 단일클론 항체 및 이의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003076569A2 (en) * 2002-03-05 2003-09-18 Genentech, Inc. Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same
CN1544465A (zh) * 2003-11-21 2004-11-10 中国科学院上海生命科学研究院 一种促进神经分化和抗细胞凋亡的蛋白质及其编码基因
CN104768974A (zh) * 2012-08-22 2015-07-08 瑞泽恩制药公司 GFRα3的人抗体及其使用方法
CN109069636A (zh) * 2016-03-04 2018-12-21 恩格姆生物制药公司 用于调节体重的组合物和方法

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO1994003599A1 (fr) 1992-08-04 1994-02-17 Sagami Chemical Research Center ADNc HUMAIN ET PROTEINE POUR LAQUELLE CODE CET ADNc
US6180602B1 (en) 1992-08-04 2001-01-30 Sagami Chemical Research Center Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent
JPH07258293A (ja) 1994-03-23 1995-10-09 Asahi Chem Ind Co Ltd 新規な蛋白質ならびにその製造方法
AU1830195A (en) 1994-12-15 1996-07-03 Human Genome Sciences, Inc. Prostatic growth factor
US6521227B1 (en) 1999-11-18 2003-02-18 Peter L. Hudson Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
US5994102A (en) 1994-12-15 1999-11-30 Human Genome Sciences, Inc. Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
DE69637844D1 (de) 1995-06-22 2009-04-09 St Vincent S Hospital Sidney L Neues tgf-beta-ahnliches cytokin
AU718979B2 (en) 1995-11-13 2000-05-04 Urmas Arumae Glial cell line-derived neurotrophic factor receptors
US6696259B1 (en) 1995-11-13 2004-02-24 Licentia Ltd. Assays using glial cell line-derived neurotrophic factor receptors
US6524802B1 (en) 1996-03-29 2003-02-25 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-14
JP2001500732A (ja) 1996-09-11 2001-01-23 オーソ―マクニール・フアーマシユーチカル・インコーポレーテツド 前立腺がんを治療するためのＴＮＦ―β様タンパク質、ならびに関連する核酸分子、医薬組成物および方法
CA2289116A1 (en) 1997-05-06 1998-11-12 Human Genome Sciences, Inc. Enterococcus faecalis polynucleotides and polypeptides
EP1007072A4 (en) 1997-05-22 2002-06-26 Cephalon Inc RECEPTORS NEUROTROPHER FACTORS FROM A GLIA CELL LINE
AU8591198A (en) 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
WO2000005259A1 (en) 1998-07-23 2000-02-03 Smithkline Beecham Corporation Secreted cysteine rich protein-6 (scrp-6)
US6905817B1 (en) 1998-10-01 2005-06-14 Licestia Ltd. Ret-independent signaling pathway for GDNF
WO2000020867A1 (en) 1998-10-01 2000-04-13 Alexey Vladimirovich Titievsky A novel ret-independent signaling pathway for gdnf
US6465181B2 (en) 1999-03-25 2002-10-15 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
US6974684B2 (en) 2001-08-08 2005-12-13 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
ES2275513T3 (es) 1999-05-17 2007-06-16 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh Propiedades neuroprotectoras de gdf-15, un miembro de la superfamilia de tgf-beta.
US6866851B1 (en) 1999-12-28 2005-03-15 Washington University GFRα1-RET specific agonists and methods therefor
EP2206720A1 (en) 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
DE60142372D1 (de) 2000-04-20 2010-07-22 St Vincents Hosp Sydney Diagnostischer Assay mit makrophagenhemmendem Zytokin-1 (MIC-1)
US7141661B2 (en) 2000-09-08 2006-11-28 The United States Of America As Represented By The Department Of Health And Human Services Non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
US7276593B2 (en) 2000-12-29 2007-10-02 Curagen Corporation Proteins and nucleic acids encoding same
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7511121B2 (en) 2001-03-09 2009-03-31 Arnason Barry G W Polymeric immunoglobulin fusion proteins that target low-affinity Fcγreceptors
ATE549354T1 (de) 2001-05-11 2012-03-15 Amgen Inc Peptide und damit zusammenhängende an tall-1 bindende moleküle
GB0115195D0 (en) 2001-06-21 2001-08-15 Bae Systems Plc Split-pin drill jig
US20030053431A1 (en) 2001-09-10 2003-03-20 Lila Madour Method for performing handoff in a radio telecommunications network
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
US20060253913A1 (en) 2001-12-21 2006-11-09 Yue-Jin Huang Production of hSA-linked butyrylcholinesterases in transgenic mammals
US20100285016A1 (en) 2002-03-05 2010-11-11 Genentech, Inc. PRO34128 nucleic acids
US7576185B2 (en) * 2002-03-05 2009-08-18 Genentech, Inc. PRO34128 antibodies
US7157235B2 (en) 2002-06-17 2007-01-02 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
US7919084B2 (en) 2002-06-17 2011-04-05 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
CN1241946C (zh) 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
WO2004043385A2 (en) 2002-11-08 2004-05-27 Barnes-Jewish Hospital Methods and compositions for prostate epithelial cell differentiation
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
EP1734986B1 (en) 2004-04-13 2015-11-11 St Vincent's Hospital Sydney Limited Method for modulating appetite
WO2005113585A2 (en) 2004-05-20 2005-12-01 Acceleron Pharma Inc. Modified tgf-beta superfamily polypeptides
DK1844337T3 (da) 2005-01-24 2013-09-30 Pepscan Systems Bv Bindingsforbindelser, immunogene forbindelser og peptidmimetika
AU2006291990B2 (en) * 2005-09-13 2012-05-31 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
EP2004683B1 (en) 2006-03-24 2016-05-11 Biogen Hemophilia Inc. Pc5 as a factor ix propeptide processing enzyme
US8974748B2 (en) 2007-04-05 2015-03-10 Corning Incorporated Dual inlet microchannel device and method for using same
EP2082645A1 (en) 2006-04-19 2009-07-29 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
US7754689B2 (en) 2006-06-02 2010-07-13 Wyeth Llc Finger-1 peptide analogs of the TGF-β superfamily
CA2659225A1 (en) 2006-07-26 2008-01-31 Pepscan Systems B.V. Immunogenic compounds and protein mimics
ATE511656T1 (de) 2006-08-04 2011-06-15 Hannover Med Hochschule Verfahren zur risikobewertung von herzeingriffen auf gdf-15-basis
AR063494A1 (es) 2006-10-19 2009-01-28 Genentech Inc Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
AU2007352480B2 (en) 2007-04-25 2012-06-21 Stem Cells Spin Sa New stem cell lines, their application and culture methods
WO2009012600A1 (en) 2007-07-26 2009-01-29 Novagen Holding Corporation Fusion proteins
US20100278843A1 (en) 2007-08-16 2010-11-04 St. Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
US20100266707A1 (en) 2007-10-09 2010-10-21 Samuel Norbert Breit Method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1
CN101861522B (zh) 2007-10-22 2014-05-14 圣文森特医院悉尼有限公司 预后方法
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
WO2009087190A1 (en) 2008-01-08 2009-07-16 Roche Diagnostics Gmbh Means and methods for assessing the risk of patients presenting to emergency units based on gdf-15
CA2711503A1 (en) 2008-01-08 2009-07-16 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
WO2009126709A1 (en) 2008-04-09 2009-10-15 Transtech Pharma, Inc. Ligands for the glp-1 receptor and methods for discovery thereof
JP2011523051A (ja) 2008-05-20 2011-08-04 エフ．ホフマン−ラ ロシュ アーゲー １型糖尿病におけるバイオマーカーとしてのｇｄｆ−１５
JP2011528115A (ja) 2008-07-14 2011-11-10 エフ．ホフマン−ラ ロシュ アーゲー 心不全を有する患者の診断、モニター及び治療の選択のためのマルチマーカーパネル
WO2010019263A2 (en) 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers
JP5444363B2 (ja) 2008-10-31 2014-03-19 セントビンセンツ ホスピタル シドニー リミテッド 慢性腎疾患における予後判定の方法
MX349178B (es) 2008-10-31 2017-07-17 Centocor Ortho Biotech Inc Diferenciación de células madre embrionarias humanas al linaje endocrino pancreático.
EP2209003A1 (en) 2009-01-16 2010-07-21 F. Hoffmann-Roche AG Means and methods for differentiating between fibrosis and cirrhosis
EP2211182A1 (en) 2009-01-16 2010-07-28 Roche Diagnostics GmbH Method for the assessment of severity of liver cirrhosis
WO2010093925A2 (en) 2009-02-12 2010-08-19 Stryker Corporation PERIPHERAL ADMINISTRATION OF PROTEINS INCLUDING TGF-β SUPERFAMILY MEMBERS FOR TREATMENT OF SYSTEMIC DISORDERS AND DISEASE
GB0902737D0 (en) 2009-02-19 2009-04-01 Univ Gent GDF15 as a differential marker for spondyloarthropathy
EP2401293B1 (en) 2009-02-24 2016-02-10 The Salk Institute For Biological Studies Designer ligands of tgf-beta superfamily
HRP20240135T1 (hr) 2009-05-05 2024-04-12 Amgen Inc. Fgf21 mutanti i njihove upotrebe
CA2766166A1 (en) 2009-07-08 2011-01-13 Amgen Inc. Design of stable and aggregation free antibody fc molecules through ch3 domain interface engineering
US20130323835A1 (en) 2009-07-15 2013-12-05 Zirus, Inc. Mammalian Genes Involved in Infection
WO2011050407A1 (en) 2009-10-28 2011-05-05 St Vincent's Hospital Sydney Limited Methods of diagnosing and prognosing colonic polyps
BR112012010153B1 (pt) 2009-11-05 2022-05-03 Genentech, Inc Método de produção de um anticorpo
WO2011064758A2 (en) 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
EP2540827A4 (en) 2010-02-26 2013-09-04 Chugai Pharmaceutical Co Ltd ANTI-ICAM3 ANTIBODY AND ITS USE
US9212221B2 (en) 2010-03-03 2015-12-15 Detroit R & D, Inc. Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses
JP5791335B2 (ja) 2010-04-07 2015-10-07 花王株式会社 オルガノポリシロキサン化合物の製造方法
US20130202564A1 (en) 2010-04-09 2013-08-08 University Of Southern California Systems and Methods of Cell Activated, Controlled Release Delivery of Growth Factors for Tissue Repair and Regeneration
EP2383571A1 (en) 2010-05-02 2011-11-02 Prof. Hess Medical Consulting GmbH Growth differntioation factor 15 (GDF 15) for risk prediction of diabetic foot ulcer
CN105044349B (zh) 2010-08-26 2018-04-06 弗·哈夫曼-拉罗切有限公司 生物标志物在评估从动脉高血压向心力衰竭的早期转变中的用途
US9243057B2 (en) * 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
EP2439535A1 (en) 2010-10-07 2012-04-11 F. Hoffmann-La Roche AG Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus
CN103533951B (zh) 2011-04-08 2017-04-19 安姆根有限公司 使用生长分化因子15(gdf‑15)治疗或改善代谢障碍的方法
RS55609B1 (sr) 2011-04-13 2017-06-30 Bristol Myers Squibb Co Fc fuzioni proteini koji sadrže nove linkere ili aranžmane
RU2013155695A (ru) 2011-06-30 2015-08-10 Дженентек, Инк. Препараты антител против с-мет
CN109517059B (zh) 2011-06-30 2023-03-28 中外制药株式会社 异源二聚化多肽
WO2013012648A1 (en) * 2011-07-15 2013-01-24 Emory University Gdf15 in diagnostic and therapeutic applications
JP2015506373A (ja) 2012-01-26 2015-03-02 アムジエン・インコーポレーテツド 成長分化因子１５（ｇｄｆ−１５）ポリペプチド
JP6254146B2 (ja) 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 代謝障害を治療するための組成物および方法
WO2013192388A1 (en) 2012-06-20 2013-12-27 University Of Virginia Patent Foundation Compositions and methods for regulating glucose homeostasis and insulin action
WO2014000042A1 (en) 2012-06-27 2014-01-03 Prince Henry's Institute Of Medical Research COMPOSITIONS AND METHODS FOR MODIFYING TGF-β FAMILY LIGANDS
UY34905A (es) * 2012-07-12 2014-01-31 Abbvie Inc Proteínas de unión a il-1
US9493562B2 (en) 2012-07-19 2016-11-15 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
CA2876285A1 (en) 2012-08-08 2014-02-13 Roche Glycart Ag Interleukin-10 fusion proteins and uses thereof
HRP20191326T1 (hr) 2012-09-26 2019-11-01 Univ Wuerzburg J Maximilians Monoklonska antitijela za faktor rasta i diferencijacije 15 (gdf-15)
AU2013334583B2 (en) 2012-10-24 2018-09-13 Research Development Foundation JAM-C antibodies and methods for treatment of cancer
US20150376294A1 (en) * 2012-12-03 2015-12-31 Rigshospitalet Anti-pad2 antibodies and treatment of autoimmune diseases
CA2896076C (en) * 2012-12-21 2022-12-06 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
DE102013100322A1 (de) 2013-01-14 2014-07-17 Claas Selbstfahrende Erntemaschinen Gmbh Schneidwerk
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
CA2899170C (en) 2013-01-30 2022-08-02 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
WO2014140374A2 (en) 2013-03-15 2014-09-18 Novo Nordisk A/S Monovalent cd27 antibodies
EP3385277A1 (en) 2013-03-15 2018-10-10 F. Hoffmann-La Roche AG Il-22 polypeptides and il-22 fc fusion proteins and methods of use
MX2015016978A (es) * 2013-06-10 2016-04-25 Merck Sharp & Dohme Proteinas de union a antigeno neutralizantes de citomegalovirus.
TWI648401B (zh) 2013-07-31 2019-01-21 安美基公司 生長分化因子１５（ｇｄｆ－１５）構築體
TWI750110B (zh) * 2014-07-21 2021-12-21 瑞士商諾華公司 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
MX370115B (es) 2014-07-30 2019-12-02 Ngm Biopharmaceuticals Inc Dímeros que comprenden dos polipéptidos, útiles en el tratamiento de trastornos metabólicos.
PL3212226T3 (pl) 2014-10-31 2020-11-02 Ngm Biopharmaceuticals, Inc. Kompozycje i sposoby stosowania w leczeniu zaburzeń metabolicznych
GB201512733D0 (en) 2015-07-20 2015-08-26 Genagon Therapeutics Ab Therapeutic agents for treating conditions associated with elevated GDF15
WO2017121865A1 (en) 2016-01-15 2017-07-20 Novo Nordisk A/S Mic-1 receptor and uses thereof
CN108697795A (zh) 2016-02-29 2018-10-23 伊莱利利公司 Gfral受体疗法
PE20190126A1 (es) * 2016-03-31 2019-01-17 Ngm Biopharmaceuticals Inc Proteinas de union y metodos de uso de las mismas
EP3526346A1 (en) 2016-10-12 2019-08-21 Janssen Biotech, Inc. Methods for screening for modulators of gdf15-like biological activity
JP7155403B2 (ja) 2018-08-20 2022-10-18 ファイザー・インク 抗ｇｄｆ１５抗体、組成物および使用の方法
WO2021246773A1 (ko) 2020-06-04 2021-12-09 재단법인대구경북과학기술원 Gfral 길항 항체 및 이의 용도
EP4304647A1 (en) 2021-03-08 2024-01-17 MedImmune, LLC Antibodies directed against gdf-15
CA3215737A1 (en) 2021-03-31 2022-10-06 Cambridge Enterprise Limited Therapeutic inhibitors of gdf15 signalling
WO2022207785A1 (en) 2021-03-31 2022-10-06 Kymab Limited Antibodies to gfral
TW202313694A (zh) 2021-09-10 2023-04-01 美商恩格姆生物製藥公司 治療癌症以及腫瘤相關之體重減輕及惡病質之方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003076569A2 (en) * 2002-03-05 2003-09-18 Genentech, Inc. Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same
CN1544465A (zh) * 2003-11-21 2004-11-10 中国科学院上海生命科学研究院 一种促进神经分化和抗细胞凋亡的蛋白质及其编码基因
CN104768974A (zh) * 2012-08-22 2015-07-08 瑞泽恩制药公司 GFRα3的人抗体及其使用方法
CN109069636A (zh) * 2016-03-04 2018-12-21 恩格姆生物制药公司 用于调节体重的组合物和方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GDF 15 deficiency induces a progressive Schwann cell loss in vivo and regulates their survival and migration in vitro;Sabrina Walter;Universitätsbibliothek Heidelberg;摘要 *
GDF15 promotes EMT and metastasis in colorectal cancer;Chen Li等;Oncotarget;第7卷(第7期);摘要 *
Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients;Lorena Lerner等;《J Cachexia Sarcopenia Muscle》;20151231;第6卷(第4期);第317-324页 *
绵羊Gfral基因的克隆和多克隆抗体的制备及应用;刘燕;《中国优秀硕士学位论文全文数据库 业科技辑》;20130115(第1期);D050-85 *

Also Published As

Publication number Publication date
KR102630655B1 (ko) 2024-01-30
IL261666B1 (en) 2024-05-01
PE20190126A1 (es) 2019-01-17
JP2024156852A (ja) 2024-11-06
IL261666B2 (en) 2024-09-01
TW201809011A (zh) 2018-03-16
CN117986363A (zh) 2024-05-07
WO2017172260A8 (en) 2017-12-28
KR102370762B1 (ko) 2022-03-04
CO2018009995A2 (es) 2018-12-14
AU2017241161A1 (en) 2018-09-20
IL261666A (en) 2018-10-31
TW202423985A (zh) 2024-06-16
WO2017172260A1 (en) 2017-10-05
RU2018132739A3 (https=) 2020-09-02
RU2018132739A (ru) 2020-04-30
AU2022224794A1 (en) 2022-09-22
US20250188174A1 (en) 2025-06-12
US20220073627A1 (en) 2022-03-10
AU2022224794B2 (en) 2025-07-03
AU2017241161C1 (en) 2026-03-12
US10975154B2 (en) 2021-04-13
JP7021099B2 (ja) 2022-02-18
AU2025234197A1 (en) 2025-10-16
NZ745635A (en) 2024-03-22
TWI815793B (zh) 2023-09-21
AU2017241161B2 (en) 2022-05-26
EP3436068A1 (en) 2019-02-06
CL2018002687A1 (es) 2019-05-10
US20190092866A1 (en) 2019-03-28
PH12018501882A1 (en) 2019-01-28
US20170306031A1 (en) 2017-10-26
US10174119B2 (en) 2019-01-08
KR20180130524A (ko) 2018-12-07
BR112018068898A2 (pt) 2019-01-22
US12180289B2 (en) 2024-12-31
KR20220032645A (ko) 2022-03-15
NZ785098A (en) 2025-09-26
MX2024011328A (es) 2024-11-08
JP2019513018A (ja) 2019-05-23
JP7610541B2 (ja) 2025-01-08
CN109715206A (zh) 2019-05-03
MX2018011503A (es) 2018-11-09
TWI897070B (zh) 2025-09-11
JP2022088355A (ja) 2022-06-14
EP3436068A4 (en) 2020-01-15
MY194669A (en) 2022-12-12
SG11201807279QA (en) 2018-09-27
CA3016035A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
CN109715206B (zh) 结合蛋白及其使用方法
US12378312B2 (en) Polynucleotides encoding human beta klotho antibodies or binding fragments thereof and methods of use thereof
US11667708B2 (en) Anti-human beta klotho antibody or binding fragment thereof and methods of their use
RU2786909C2 (ru) Связывающие белки и способы их применения
HK40036377A (en) Antibodies binding beta klotho domain 2 and methods of use thereof
HK1229825B (en) Antibodies binding beta klotho domain 2 and methods of use thereof
HK1229825A1 (en) Antibodies binding beta klotho domain 2 and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment